Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While DSIP was originally described for inducing spindle and delta sleep activity when infused into the brain of rabbits; later studies report stress-modulating and endocrine effects, though its physiological role is still debated47, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While DSIP works as an endogenous nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, with proposed neuromodulatory actions; it interacts with components of the MAPK cascade and may be related to glucocorticoid-induced leucine zipper (GILZ), but its precise biosynthetic origin remains unknown4757, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
DSIP
Not assigned in the current dataset.
Liraglutide
GCG
DSIP and Liraglutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: DSIP is more often discussed in the realm of Neurology and brain health, whereas Liraglutide is more often associated with the realm of Metabolic and endocrine. Their biological logic is quite different: DSIP is a neurotransmitter modulator, whereas Liraglutide is a receptor agonist and a hormone analog. DSIP has a more natural endogenous origin, while Liraglutide is closer to synthetic analog background and their development context also differs, with DSIP approved for Research use only while Liraglutide is approved. DSIP takes the form of a linear peptide, whereas Liraglutide is closer to a peptide conjugate, while Liraglutide incorporates palmitoylation features that are not part of DSIP.